Holen Sie sich die Stockscreener-App
4.14
3.50%
0.14
Vorhandelsmarkt:
4.16
0.02
+0.48%
Schlusskurs vom Vortag:
$4.00
Offen:
$4.1
24-Stunden-Volumen:
206.96K
Relative Volume:
1.14
Marktkapitalisierung:
$70.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+11.29%
1M Leistung:
+30.19%
6M Leistung:
+20.70%
1J Leistung:
-0.96%
1-Tages-Spanne:
$3.89
$4.18
1-Wochen-Bereich:
$3.55
$4.18
52-Wochen-Spanne:
$2.87
$5.623
Mural Oncology Plc Stock (MURA) Company Profile
Firmenname
Mural Oncology Plc
Sektor
Branche
Telefon
353 1 905 8020
Adresse
10 EARLSFORT TERRACE, DUBLIN 2
Vergleichen Sie MURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
4.14 | 70.63M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-04 | Eingeleitet | Morgan Stanley | Overweight |
Mural Oncology Plc Aktie (MURA) Neueste Nachrichten
Geode Capital Management LLC Purchases 4,731 Shares of Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts - The Manila Times
Mural Oncology Expands Pipeline with Two Novel Cancer Therapies, Advances Key Clinical Trials - StockTitan
Mural Oncology's chief legal officer sells $8,354 in shares By Investing.com - Investing.com Australia
Mural Oncology's chief legal officer sells $8,354 in shares - Investing.com India
Fmr LLC Grows Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
BNP Paribas Financial Markets Lowers Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology stock hits 52-week low at $2.87 By Investing.com - Investing.com UK
Mural Oncology CEO Caroline Loew sells shares worth $9,394 - Investing.com
Mural Oncology CEO Caroline Loew sells shares worth $9,394 By Investing.com - Investing.com UK
Mural Oncology plc (NASDAQ:MURA) Shares Sold by Verition Fund Management LLC - MarketBeat
Mural Oncology GAAP EPS of -$1.84; reaffirms financial guidance - MSN
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mural Oncology Awards Key Talent with Stock Options and RSU Inducement Grants - StockTitan
Analysts Give Strong Buy Rating To This Undervalued Medical Stock (MURA) With Up To 350% Of Share Price Upside - Benzinga
Alkermes to Participate in Upcoming Investor Conferences - Quantisnow
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Rodman & Renshaw Initiates Coverage of Mural Oncology (MURA) with Buy Recommendation - MSN
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer - The Manila Times
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News - StockTitan
HC Wainwright Raises Earnings Estimates for Mural Oncology - Defense World
HC Wainwright Predicts Stronger Earnings for Mural Oncology - MarketBeat
MURAMural Oncology plc Ordinary Shares Latest Stock News & Market Updates - StockTitan
Armistice Capital, LLC Increases Stake in Mural Oncology PLC - GuruFocus.com
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress - The Manila Times
Mural Oncology plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mural Oncology Reports 38% Lower Net Loss, Hits Trial Enrollment Milestones in Q3 | MURA Stock News - StockTitan
HC Wainwright Reaffirms "Buy" Rating for Mural Oncology (NASDAQ:MURA) - MarketBeat
Mural Oncology to Participate in Two Upcoming Investor Conferences - The Manila Times
Mural Oncology (MURA) to Present at Major Healthcare Investor Conferences | MURA Stock News - StockTitan
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times
Mural Oncology Reports Promising Cancer Trial Data, Plans Key 2025 Readouts | MURA Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Mural Oncology PLC H - GuruFocus.com
Mural Oncology CFO Adam Cutler sells $25,305 in company stock By Investing.com - Investing.com Canada
Mural Oncology plc (NASDAQ:MURA) CFO Adam D. Cutler Sells 7,421 Shares - MarketBeat
Mural Oncology CFO Adam Cutler sells $25,305 in company stock - Investing.com
Short Interest in Mural Oncology plc (NASDAQ:MURA) Decreases By 15.7% - MarketBeat
HC Wainwright Comments on Mural Oncology Q3 Earnings - MarketBeat
Mural Oncology (NASDAQ:MURA) Coverage Initiated at HC Wainwright - MarketBeat
H.C. Wainwright initiates coverage on Mural Oncology stock with Buy rating - Investing.com UK
167,644 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Squarepoint Ops LLC - MarketBeat
232,100 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Renaissance Technologies LLC - MarketBeat
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times
Raymond James Begins Coverage on Mural Oncology (NASDAQ:MURA) - Defense World
Mural Oncology (NASDAQ:MURA) Coverage Initiated by Analysts at Raymond James - MarketBeat
Finanzdaten der Mural Oncology Plc-Aktie (MURA)
Es liegen keine Finanzdaten für Mural Oncology Plc (MURA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):